AAPL302.22+7.84 (+2.66%) ▲|ABBV254.12+3.06 (+1.22%) ▲|ABT92.26+0.08 (+0.09%) ▲|ACN134.93+3.80 (+2.90%) ▲|ADBE218.27+7.29 (+3.45%) ▲|AMAT643.04-7.87 (-1.21%) ▼|AMD536.49-4.39 (-0.81%) ▼|AMGN368.12+6.79 (+1.88%) ▲|AMT168.16+2.08 (+1.25%) ▲|AMZN243.25+1.55 (+0.64%) ▲|AVGO371.12+1.78 (+0.48%) ▲|AXP347.44+0.39 (+0.11%) ▲|BA226.81+8.23 (+3.77%) ▲|BAC58.13-0.23 (-0.39%) ▼|BKNG183.59+0.95 (+0.52%) ▲|BLK993.05+12.67 (+1.29%) ▲|BMY57.29+1.48 (+2.64%) ▲|BNY146.75+0.73 (+0.50%) ▲|BRK-B502.35+2.61 (+0.52%) ▲|C140.79+0.66 (+0.47%) ▲|CAT996.12+4.71 (+0.48%) ▲|CL93.74+0.98 (+1.06%) ▲|CMCSA23.66-0.08 (-0.32%) ▼|COF205.69+0.87 (+0.42%) ▲|COP104.22+1.00 (+0.97%) ▲|COST928.04+3.37 (+0.36%) ▲|CRM164.80+1.57 (+0.96%) ▲|CSCO115.66-1.36 (-1.16%) ▼|CVS104.58-0.23 (-0.22%) ▼|CVX168.85+3.16 (+1.91%) ▲|DE637.07+9.44 (+1.50%) ▲|DHR195.65+1.93 (+1.00%) ▲|DIS95.91+0.20 (+0.21%) ▲|DUK126.61+0.84 (+0.67%) ▲|EMR141.47+1.95 (+1.40%) ▲|FDX314.92+1.03 (+0.33%) ▲|GD368.81+6.02 (+1.66%) ▲|GE380.72+5.79 (+1.54%) ▲|GEV1,129.86-4.87 (-0.43%) ▼|GILD127.56+1.59 (+1.26%) ▲|GM75.95+0.41 (+0.54%) ▲|GOOG360.11+2.22 (+0.62%) ▲|GOOGL363.47+2.26 (+0.63%) ▲|GS1,036.49+16.78 (+1.65%) ▲|HD349.32-1.58 (-0.45%) ▼|HON223.68+1.93 (+0.87%) ▲|IBM289.12+2.85 (+1.00%) ▲|INTC129.09+2.07 (+1.63%) ▲|INTU271.60+4.52 (+1.69%) ▲|ISRG411.44+9.06 (+2.25%) ▲|JNJ256.99+3.04 (+1.20%) ▲|JPM332.92-1.16 (-0.35%) ▼|KO81.63+0.32 (+0.39%) ▲|LIN540.54+6.99 (+1.31%) ▲|LLY1,208.63+16.72 (+1.40%) ▲|LMT538.92+17.22 (+3.30%) ▲|LOW222.13+0.26 (+0.12%) ▲|LRCX384.51-6.75 (-1.73%) ▼|MA527.43+4.93 (+0.94%) ▲|MCD272.63+3.16 (+1.17%) ▲|MDLZ60.15+0.80 (+1.35%) ▲|MDT80.04+0.83 (+1.05%) ▲|META592.61-20.30 (-3.31%) ▼|MMM160.82+0.77 (+0.48%) ▲|MO72.28+0.72 (+1.01%) ▲|MRK127.22+1.81 (+1.44%) ▲|MS214.77+2.92 (+1.38%) ▲|MSFT385.47+1.19 (+0.31%) ▲|MU1,056.49+24.21 (+2.35%) ▲|NEE86.90+0.51 (+0.59%) ▲|NFLX75.51+1.32 (+1.78%) ▲|NKE44.70+1.56 (+3.60%) ▲|NOW105.74-0.03 (-0.03%) ▼|NVDA197.98+0.40 (+0.20%) ▲|ORCL145.80+3.07 (+2.15%) ▲|PEP142.82+1.66 (+1.18%) ▲|PFE24.33+0.44 (+1.82%) ▲|PG148.47+1.03 (+0.70%) ▲|PLTR130.68+4.95 (+3.94%) ▲|PM180.90+3.22 (+1.81%) ▲|QCOM182.72+0.80 (+0.44%) ▲|RTX196.83+5.06 (+2.64%) ▲|SBUX103.76+0.37 (+0.35%) ▲|SCHW96.46+0.69 (+0.72%) ▲|SO95.68+0.55 (+0.57%) ▲|SPG223.60+0.51 (+0.23%) ▲|T20.89+0.40 (+1.93%) ▲|TMO520.70+7.20 (+1.40%) ▲|TMUS176.00+2.94 (+1.70%) ▲|TSLA412.61-12.69 (-2.98%) ▼|TXN303.63+5.22 (+1.75%) ▲|UBER73.32+0.65 (+0.89%) ▲|UNH429.13+2.70 (+0.63%) ▲|UNP281.81+4.10 (+1.47%) ▲|UPS110.54+1.04 (+0.95%) ▲|USB61.99+0.03 (+0.05%) ▲|V354.78+3.68 (+1.05%) ▲|VZ42.81+0.82 (+1.95%) ▲|WFC85.72-0.23 (-0.26%) ▼|WMT110.79+1.97 (+1.81%) ▲|XOM138.51+2.23 (+1.63%) ▲|AAPL302.22+7.84 (+2.66%) ▲|ABBV254.12+3.06 (+1.22%) ▲|ABT92.26+0.08 (+0.09%) ▲|ACN134.93+3.80 (+2.90%) ▲|ADBE218.27+7.29 (+3.45%) ▲|AMAT643.04-7.87 (-1.21%) ▼|AMD536.49-4.39 (-0.81%) ▼|AMGN368.12+6.79 (+1.88%) ▲|AMT168.16+2.08 (+1.25%) ▲|AMZN243.25+1.55 (+0.64%) ▲|AVGO371.12+1.78 (+0.48%) ▲|AXP347.44+0.39 (+0.11%) ▲|BA226.81+8.23 (+3.77%) ▲|BAC58.13-0.23 (-0.39%) ▼|BKNG183.59+0.95 (+0.52%) ▲|BLK993.05+12.67 (+1.29%) ▲|BMY57.29+1.48 (+2.64%) ▲|BNY146.75+0.73 (+0.50%) ▲|BRK-B502.35+2.61 (+0.52%) ▲|C140.79+0.66 (+0.47%) ▲|CAT996.12+4.71 (+0.48%) ▲|CL93.74+0.98 (+1.06%) ▲|CMCSA23.66-0.08 (-0.32%) ▼|COF205.69+0.87 (+0.42%) ▲|COP104.22+1.00 (+0.97%) ▲|COST928.04+3.37 (+0.36%) ▲|CRM164.80+1.57 (+0.96%) ▲|CSCO115.66-1.36 (-1.16%) ▼|CVS104.58-0.23 (-0.22%) ▼|CVX168.85+3.16 (+1.91%) ▲|DE637.07+9.44 (+1.50%) ▲|DHR195.65+1.93 (+1.00%) ▲|DIS95.91+0.20 (+0.21%) ▲|DUK126.61+0.84 (+0.67%) ▲|EMR141.47+1.95 (+1.40%) ▲|FDX314.92+1.03 (+0.33%) ▲|GD368.81+6.02 (+1.66%) ▲|GE380.72+5.79 (+1.54%) ▲|GEV1,129.86-4.87 (-0.43%) ▼|GILD127.56+1.59 (+1.26%) ▲|GM75.95+0.41 (+0.54%) ▲|GOOG360.11+2.22 (+0.62%) ▲|GOOGL363.47+2.26 (+0.63%) ▲|GS1,036.49+16.78 (+1.65%) ▲|HD349.32-1.58 (-0.45%) ▼|HON223.68+1.93 (+0.87%) ▲|IBM289.12+2.85 (+1.00%) ▲|INTC129.09+2.07 (+1.63%) ▲|INTU271.60+4.52 (+1.69%) ▲|ISRG411.44+9.06 (+2.25%) ▲|JNJ256.99+3.04 (+1.20%) ▲|JPM332.92-1.16 (-0.35%) ▼|KO81.63+0.32 (+0.39%) ▲|LIN540.54+6.99 (+1.31%) ▲|LLY1,208.63+16.72 (+1.40%) ▲|LMT538.92+17.22 (+3.30%) ▲|LOW222.13+0.26 (+0.12%) ▲|LRCX384.51-6.75 (-1.73%) ▼|MA527.43+4.93 (+0.94%) ▲|MCD272.63+3.16 (+1.17%) ▲|MDLZ60.15+0.80 (+1.35%) ▲|MDT80.04+0.83 (+1.05%) ▲|META592.61-20.30 (-3.31%) ▼|MMM160.82+0.77 (+0.48%) ▲|MO72.28+0.72 (+1.01%) ▲|MRK127.22+1.81 (+1.44%) ▲|MS214.77+2.92 (+1.38%) ▲|MSFT385.47+1.19 (+0.31%) ▲|MU1,056.49+24.21 (+2.35%) ▲|NEE86.90+0.51 (+0.59%) ▲|NFLX75.51+1.32 (+1.78%) ▲|NKE44.70+1.56 (+3.60%) ▲|NOW105.74-0.03 (-0.03%) ▼|NVDA197.98+0.40 (+0.20%) ▲|ORCL145.80+3.07 (+2.15%) ▲|PEP142.82+1.66 (+1.18%) ▲|PFE24.33+0.44 (+1.82%) ▲|PG148.47+1.03 (+0.70%) ▲|PLTR130.68+4.95 (+3.94%) ▲|PM180.90+3.22 (+1.81%) ▲|QCOM182.72+0.80 (+0.44%) ▲|RTX196.83+5.06 (+2.64%) ▲|SBUX103.76+0.37 (+0.35%) ▲|SCHW96.46+0.69 (+0.72%) ▲|SO95.68+0.55 (+0.57%) ▲|SPG223.60+0.51 (+0.23%) ▲|T20.89+0.40 (+1.93%) ▲|TMO520.70+7.20 (+1.40%) ▲|TMUS176.00+2.94 (+1.70%) ▲|TSLA412.61-12.69 (-2.98%) ▼|TXN303.63+5.22 (+1.75%) ▲|UBER73.32+0.65 (+0.89%) ▲|UNH429.13+2.70 (+0.63%) ▲|UNP281.81+4.10 (+1.47%) ▲|UPS110.54+1.04 (+0.95%) ▲|USB61.99+0.03 (+0.05%) ▲|V354.78+3.68 (+1.05%) ▲|VZ42.81+0.82 (+1.95%) ▲|WFC85.72-0.23 (-0.26%) ▼|WMT110.79+1.97 (+1.81%) ▲|XOM138.51+2.23 (+1.63%) ▲|
34.6 C
New York
Thursday, July 2, 2026

Tag: meeting

newssourceFORcompanyinformationcontent1releasesmarket

Sobi and Apellis: Aspaveli®/Empaveli® Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases

STOCKHOLM, June 6, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase...

Immix Biopharma Attends FDA CEO Forum in Washington DC

– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D., M.P.H. –

Davis Commodities Plans to Establish Bitcoin Reserves to Strengthen Asset Allocation

Davis Commodities (DTCK) plans to establish Bitcoin reserves.

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

WALTHAM, Mass. and STOCKHOLM, June 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today presented new data from the open-label period of the Phase 3 VALIANT study, investigating EMPAVELI® (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The data were presented as part of a late-breaking session at the European Renal Association (ERA) Congress.

Lung Cancer Patient Advocates Join World’s Largest Oncology Conference

LiveLung 'ASCO Scholars' Share Experience at Educational Meeting CHICAGO, June 6, 2025 /PRNewswire/ -- Six lung cancer patients and one care partner were selected as...

Blockchain and Digital Assets Virtual Investor Conference: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

Improved Pharma Expands Footprint at Kurz Purdue Technology Center, Now Occupying Over 5,500 Square Feet

Fifth expansion since 2020 reflects growing demand for advanced pharmaceutical analysis and development services. WEST LAFAYETTE, Ind., June 6, 2025 /PRNewswire/ -- Improved Pharma LLC...

iGlobal Media USA Opens $500,000 Investment Round to Fuel National Expansion of Digital Radio Platform

LOS ANGELES, June 6, 2025 /PRNewswire/ -- iGlobal Media USA, a rapidly growing digital broadcasting company, today announced the opening of a $500,000 investment round...

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine –

Cashco Financial Releases 5th Annual Pathway Report: Pathway 2024 – Moving Canadians Forward

EDMONTON, AB, June 6, 2025 /CNW/ - Cashco Financial proudly releases its 5th annual Pathway Report, titled "Pathway 2024: Moving Canadians Forward." This edition...

Quantum Metal Recovery Inc. Responds to Besra Gold’s ASX Announcement, Initiates Legal Proceedings in Ontario

PENANG, Malaysia, June 6, 2025 /PRNewswire/ -- Quantum Metal Recovery Inc. (QMRI), the largest shareholder of Besra Gold Inc. (Besra), has issued a formal...

GenEditBio Announces First Patient Dosed in Investigator-Initiated Trial of GEB‑101, World’s First In Vivo CRISPR-Cas Ribonucleoprotein-Based Genome Editing Investigational Therapy for TGFBI Corneal Dystrophy

HONG KONG, BEIJING and BOSTON, June 6, 2025 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions...

/C O R R E C T I O N from Source — Ario Khoshbin/

In the news release, Ario Khoshbin Files Oppression Lawsuit Following Removal as CEO of Prollenium, issued 16-May-2025 by Ario Khoshbin over PR Newswire, we are...

ANNOUNCEMENT Valuation of settlement assets

ÍL Fund, as issuer of bonds in series HFF150434 and HFF150644, has decided to exercise its settlement authorisation on 12 June 2025 in accordance with item (i) of Article 7.A of the terms of the bonds, which was agreed to be added as a temporary provision at the Meeting of Noteholders held 10 April 2025. 

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMeeting

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers